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Introduction {#s1}
============

Cardiovascular diseases (CVD) are the leading cause of death worldwide, resulting in 17.9 million deaths in 2015^[@R1]^ and expectedly exceeding 23.6 million by 2030.^[@R2]^

Some medicinal plants and food components (as monotherapy or adjunct to standard pharmacotherapy) have traditionally been used to treat CVD and have demonstrated various cardiovascular pharmacological effects.^[@R3]-[@R6]^ *Emblica officinalis* is one of the medicinal plants whose cardiovascular effects have been considered both in the traditional medicine and in the modern scientific literature.

*Emblica officinalis* Gaertn. (Other names: *Phyllanthus emblica* Linn. and *Emblica pectinata* Ridl.) (family Euphorbiaceae), also known as Emblic myrobalan, Indian gooseberry, or amla, hereafter referred to as EO. This medium-sized deciduous tree is native to India and cultivated in Pakistan, Uzbekistan, Sri Lanka, South East Asia, China, and Malaysia.^[@R7]^ The EO fruits are used more than the other parts of the plant for treatment of various diseases in the Ayurveda and Unani medicines.^[@R7]^ The dried fruit is a common imported herbal product in the herbal markets of Iran. The fresh fruits resemble green sour plums about the size of a walnut ([Figure 1](#F1){ref-type="fig"}). The fruit contains tannins, alkaloids, phenols, amino acids, carbohydrates, vitamins, flavonoids, and organic acids ([Table 1](#T1){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}).^[@R8],[@R9]^ The fruit is highly nutritious and consumed as a food.^[@R10],[@R11]^
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###### Compounds of *Emblica officinalis*

  ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Class of compounds**   **Compounds**
  Hydrolysable tannins     Emblicanin A and B, punigluconin, pedunculagin, chebulinic acid (ellagitannin), chebulagic acid (benzopyran tannin), corilagin (ellagitannin), geraniin (dehydroellagitannin), ellagotannin
  Alkaloids                Phyllantine, phyllembein, phyllantidine
  Phenols                  Gallic acids, methyl gallate, ellagic acid, trigallayl glucose
  Amino acids              Glutamic acid, proline, aspartic acid, alanine, cystine, lysine
  Carbohydrates            Pectin
  Vitamins                 Ascorbic acid
  Flavonoids               Quercetin, kaempferol
  Organic acids            Citric acids
  ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The EO fruit has also been mentioned in the literature of the Persian medicine (PM).^[@R12]^ EO is one of the 50 cardio-active plants mentioned in the Avicenna book "The Treatise on Cardiac Drugs".^[@R13]^ Cardiotonic action is one of the features attributed to this plant in the PM.^[@R12]-[@R14]^ From the PM perspective, the fruit can be cardiotonic because it has astringent properties and can strengthen the cardiac tissue.^[@R15]^ Besides, it can affect the heart by exerting impact on stomach diseases (including gastro-esophageal reflux and mal-temperaments of the stomach, which are, as noted, related to cardiac diseases).^[@R14]^ Pharmacological studies have demonstrated diverse cardiovascular and other impacts for the fruit such as cytotoxic, hypoglycemic, hypolipidemic, hepatoprotective, cardioprotective, antiatherogenic, antioxidant, antipyretic, analgesic, antimicrobial, diuretic, and laxative effects.^[@R7],[@R16]-[@R18]^

Numerous studies have been published on the effects of EO on various CVD; however, there has been no systematic review regarding the cardiovascular effects of EO nor is there a definitive decision on the efficacy of this plant. Therefore, this review was conducted to evaluate the plant potential for prevention and treatment of CVD.

Materials and Methods {#s2}
=====================

To collect the studies on the cardiovascular effects of EO, PubMed, Science Direct, Scopus, Proquest, Ebsco, Google, Google Scholar, Ovid, and Cochrane databases were searched for the English and non-English literature from 1966 to 2017 using the terms amla, Emblic myrobalan, *Emblica officinalis*, *Emblica pectinata*, Indian gooseberry, and *Phyllanthus emblica* together with antioxidant, arrhythmia, cardioprotective, cardiotoxicity, heart disease, heart failure, hyperlipidemia, hypertension, myocardial dysfunction, and oxidative stress. The database of Irandoc and the online libraries of Iranian universities were also searched for the purposes of this study.

Three persons performed the literature search and assessment. The inclusion criteria were in vitro, animal, and clinical cardiovascular pharmacological studies conducted on EO and full-text accessibility. The exclusion criterion was studies in which a combination of EO and at least one other plant was investigated. The reference lists of the retrieved articles were searched manually for additional eligible articles. All published cardiovascular pharmacological studies fulfilling the search criteria were included in the results section.

For clinical studies, PICO was considered as patients with a type of cardiovascular disease who took the EO with or without a control group with the aim to identify changes in CVD during intervention.

The methodological quality of clinical trials was assessed by the Jadad scale in terms of the presence of randomization, masking, and accountability of all patients including withdrawals, as described in the literature.^[@R19]^ The methodological quality of animal studies was assessed by ARRIVE checklist.^[@R20]^

The PRISMA flow diagram of this review is presented in [Figure 3](#F3){ref-type="fig"}.
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Results {#s3}
=======

There were no non-English and gray literature, theses and dissertations conforming to the search criteria. Summaries of the cardiovascular pharmacological studies fulfilling the search criteria are presented in [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}.

###### Summary of the experimental pharmacological studies regarding the cardiovascular effects of *Emblica officinalis*

  ---------------------------------- ---------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author, year**                   **Methodological quality**   **Study design/participants/**\                           **Intervention/control group**                                                                                                                                           **Outcome measure**                                                                                                                                                 **Results**
                                                                  **inclusion criteria**                                                                                                                                                                                                                                                                                                                                                                                 

  Thakur CP. 1988^[@R21]^            High                         N:100 (4 groups)\                                         Group1- control group (cholestrol 0.3 g/kg)\                                                                                                                             Serum TC, TG and LDL-C;\                                                                                                                                            Decrease in serum TC and LDL-C, aortic and hepatic cholesterol, possibly through enzymatic degradation of cholesterol.\
                                                                  cholesterol-induced hypercholesterolemic albino rabbits   Group 2- *Terminalia chebula* group (*Terminalia chebula*+ cholesterol)\                                                                                                 cholesterol contents of the liver and aorta; fecal excretion of cholesterol                                                                                         No effect on fecal excretion of cholesterol.\
                                                                                                                            Group 3- *Terminalia belerica* group (*Terminalia belerica* + cholesterol)\                                                                                                                                                                                                                                                                  No effect on the serum TG.
                                                                                                                            Group 4- the amla group (1 g/kg powdered EO + cholesterol, all interventions PO daily for 16 weeks                                                                                                                                                                                                                                           

  Mathur R. 1996^[@R22]^             Medium                       N: 28 (4 groups)\                                         Group 1-(control) vehicle treated for 60 and 120 days.\                                                                                                                  Serum TC, TG, LDL-C, VLDL-C and HDL-C; liver, ventricular muscle and aortic TC,TG and phospholipids contents.                                                       Decrease in TC, TG and LDL-C levels.\
                                                                  cholesterol-induced hypercholesterolemic rabbits          Group 2- cholesterol feeding (400 mg/kg per day) for 60 and 120 days\                                                                                                                                                                                                                                                                        Decrease in the lipid levels of tissues.\
                                                                                                                            Group 3- cholesterol feeding for 60 days; afterward, cholesterol diet was withdrawn; control diet + fresh juice of EO from day 61 to day 120 (5 mL juice/kg per day).\                                                                                                                                                                       Regression of aortic plaques.\
                                                                                                                            Group 4- cholesterol feeding + EO juice from day 1 to day 120 (concurrent feeding).                                                                                                                                                                                                                                                          Increase of fecal excretion of cholesterol and phospholipid.s.

  Anila L. 2002^[@R23]^              High                         N:30 (3 groups)\                                          Group I - control\                                                                                                                                                       Serum and liver LDL-C and VLDL-C and serum HDL-C. HMG-CoA activity.                                                                                                 Decrease of LDL-C and VLDL-C in serum and liver.\
                                                                  cholesterol-induced hypercholesterolemic albino rats.     Group II- flavonoids\                                                                                                                                                                                                                                                                                                                        Unchanged serum HDL-C.\
                                                                                                                            of EO10 mg/kg /day\                                                                                                                                                                                                                                                                                                                          Inhibition of HMG-CoA and increased degradation and elimination of cholesterol.
                                                                                                                            Group III - flavonoids of *Mangifera indica*\                                                                                                                                                                                                                                                                                                
                                                                                                                            PO for 90 days                                                                                                                                                                                                                                                                                                                               

  Bhattacharya SK. 2002^[@R24]^      High                         N:62 (8 groups)\                                          Group 1-saline perfusion (SP) for 30 minutes\                                                                                                                            Cardiac SOD, catalase, glutathione peroxidase activity and lipid peroxidation                                                                                       Both EOT (50 and 100 mg/kg) and vitamin E prevented IRI-induced effects (decrease in the activities of cardiac SOD, catalase and glutathione peroxidase, and increase in lipid peroxidation)
                                                                  rat model of cardiac IRI                                  Group 2- tannoid principles of EO (EOT) (50 mg/kg) + SP\                                                                                                                                                                                                                                                                                     
                                                                                                                            Group 3-EOT (100 mg/kg) + SP\                                                                                                                                                                                                                                                                                                                
                                                                                                                            Group 4-vitamin E (200mg/kg) + SP\                                                                                                                                                                                                                                                                                                           
                                                                                                                            Group 5- IRI\                                                                                                                                                                                                                                                                                                                                
                                                                                                                            Group 6-EOT (50 mg/kg) + IRI\                                                                                                                                                                                                                                                                                                                
                                                                                                                            Group 7-EOT (100 mg/kg) + IRI\                                                                                                                                                                                                                                                                                                               
                                                                                                                            Group 8-vitamin E (200mg/kg) + IRI\                                                                                                                                                                                                                                                                                                          
                                                                                                                            All perfused twice daily for 14 days                                                                                                                                                                                                                                                                                                         

  Rajak S. 2004^[@R25]^              Medium                       N:64 rats (4 groups)\                                     Group1- normal rat\                                                                                                                                                      Myocardial TBARS (a measure of lipid peroxidation) content.\                                                                                                        No significant increase in myocardial TBARS and depletion of antioxidant enzymes were observed after IRI in the treated groups.\
                                                                  rat model of cardiac IRI                                  Group 2- EO juice 250 mg/kg/day PO for 30 days\                                                                                                                          Myocardial reduced glutathione,\                                                                                                                                    Myocyte injury was evident only in 250 mg/kg group.
                                                                                                                            Group 3- EO juice 500 mg/kg/day PO for 30 days\                                                                                                                          catalase, superoxide dismutase,\                                                                                                                                    
                                                                                                                            Group 4- EO juice 750 mg/kg/day PO for 30 days                                                                                                                           glutathione peroxidase.                                                                                                                                             

  Anthony B. 2006^[@R26]^            Medium                       N:24 (4 groups)\                                          Group 1- normal control\                                                                                                                                                 Serum TC, TG, HDL-C, LDL-C; aortic atheromatous plaque; heart, liver and kidney cholesterol contents; HMG-CoA activity                                              Decrease of serum total cholesterol, TG and LDL-C; HDL-C increase; reduction of aortic atheromatous plaques; decrease of heart, liver and kidney cholesterol contents.\
                                                                  cholesterol-induced hypercholesterolemic rabbits.         Group 2- hypercholestrlemic control (vehicle PO)\                                                                                                                                                                                                                                                                                            Inhibition of HMG-CoA.
                                                                                                                            Group 3- Ethanol extract of EO 10 mg/kg/day PO\                                                                                                                                                                                                                                                                                              
                                                                                                                            Group 4- ethanol extract of EO 20 mg/kg/day\                                                                                                                                                                                                                                                                                                 
                                                                                                                            PO for 4 months                                                                                                                                                                                                                                                                                                                              

  Patel SS. 2011^[@R27]^             Medium                       N:48 rats (4 groups)\                                     Group1- non-diabetic control Group 2-diabetic control\                                                                                                                   Body weight, lipid profile, heart rate, BP, serum LDH and creatinine kinase-MB                                                                                      EO prevented weight loss, hyperglycemia, dys-lipidemia, myocardial hypertrophy and cardiomyopathy; increased heart rate and force of contraction; Decreased BP and serum LDH and creatine kinase-MB in diabetic rats.
                                                                  rat model of diabetic-induced myocardial dysfunction      Group 3-non-diabetic treated with EO juice 1 mL/kg/day PO for 8 weeks\                                                                                                                                                                                                                                                                       
                                                                                                                            Group 4-diabetic treated with EO juice 1 mL/kg/day                                                                                                                                                                                                                                                                                           

  Bhatia J. 2011^[@R28]^             High                         N:36 (6 groups)\                                          Group 1- control group (vehicle)\                                                                                                                                        SBP, DBP, mean arterial pressure, heart rate. Oxidative stress in serum, heart and kidney. Heart and kidney weights/100 g body weight ratio                         Decrease of SBP, DBP, mean arterial pressure and heart rate.\
                                                                  rat model of DOCA-salt-induced hypertension               Group 2- DOCA 20 mg/kg SC plus\                                                                                                                                                                                                                                                                                                              Increase of endothelial nitric oxide synthase activity and serum nitric oxide levels. Decrease of serum sodium and potassium levels. Decrease of oxidative stress in serum, heart and kidney.\
                                                                                                                            1% NaCl solution PO\                                                                                                                                                                                                                                                                                                                         Decrease of renal and cardiac hypertrophy.
                                                                                                                            Groups 3--5- DOCA 20 mg/kg SC plus 1% NaCl solution and\                                                                                                                                                                                                                                                                                     
                                                                                                                            *E. officinalis* 75, 150 and 300 mg/kg/day PO,\                                                                                                                                                                                                                                                                                              
                                                                                                                            respectively\                                                                                                                                                                                                                                                                                                                                
                                                                                                                            Group 6: neither received DOCA 20 mg/kg SC nor\                                                                                                                                                                                                                                                                                              
                                                                                                                            1% NaCl solution, received only *E. officinalis* 300 mg/kg/day PO plus normal drinking water.                                                                                                                                                                                                                                                

  Ojha S. 2012^[@R29]^               High                         N:40 (4 groups)\                                          Group 1- normal saline\                                                                                                                                                  Left ventricular pressure dynamics: peak positive pressure development, peak negative pressure decline and end diastolic pressure. Antioxidant enzymes,\            Restoration of hemodynamic and left ventricular function along with preservation of antioxidants, reduction of myocyte-injury-specific marker enzymes and inhibition of lipid peroxidation in EO groups.
                                                                  rat model of isoproterenol-induced cardiotoxicity         Group 2-Hydroalcoholic extract of EO 100 mg/kg PO\                                                                                                                       superoxide dismutase, catalase and glutathione peroxidase and myocyte-injury-specific marker enzymes creatine phosphokinase-MB and lactate dehydrogenase in heart   
                                                                                                                            Group 3- EO 250 mg/kg PO\                                                                                                                                                                                                                                                                                                                    
                                                                                                                            Group 4- EO 500 mg/kg PO for 30 days with concurrent isoproterenol (85 mg/kg SC) on 29^th^ and 30^th^ days.                                                                                                                                                                                                                                  

  Santoshkumar J. 2013^[@R30]^       High                         N:30 (5 groups)\                                          Group 1- normal saline\                                                                                                                                                  Serum TC,TG, LDL-C, HDL-C and\                                                                                                                                      Decrease of TC, TG and LDL-C and atherogenic index and increase of HDL-C in EO and atorvastatin groups.
                                                                  cholesterol-induced hypercholesterolemic rats             Group 2- powdered EO 540 mg/kg/day PO with normal diet\                                                                                                                  atherogenic index                                                                                                                                                   
                                                                                                                            Group 3- high fat diet\                                                                                                                                                                                                                                                                                                                      
                                                                                                                            Group 4- high fat diet and EO 540 mg/kg/day\                                                                                                                                                                                                                                                                                                 
                                                                                                                            Group 5- high fat diet and atorvastatin 7.2 mg/kg/day, PO\                                                                                                                                                                                                                                                                                   
                                                                                                                            for 8 weeks                                                                                                                                                                                                                                                                                                                                  

  Rao TP. 2013^[@R31]^               Medium                       Human umbilical vein endothelial cells.\                  In vitro application of EO water soluble extract (1-100 μ g/mL) on HUVEC in the presence of LPS.\                                                                        LPS - induced tissue factor expression; von Willebrand factor level;\                                                                                               EO fruit extract reduced LPS - induced tissue factor expression and von Willebrand factor release in HUVEC\
                                                                  N: 40 rats (2 groups) LPS-induced endotoxemia rat model   Group 1- control\                                                                                                                                                        LPS-induced adhesion of human monocytic cells (THP-1) to\                                                                                                           and decreased LPS-induced adhesion of human monocytic cells (THP-1) to\
                                                                                                                            Group 2-\                                                                                                                                                                HUVEC; Expression of endothelial-leucocyte adhesion molecule-1 (E-selectin) in HUVEC.\                                                                              HUVEC and reduced expression of endothelial-leucocyte adhesion molecule-1 (E-selectin) in HUVEC.\
                                                                                                                            Single dose of EO water soluble extract 50 mg/kg PO                                                                                                                      Pro-inflammatory cytokines TNF-α and IL-6 serum levels.                                                                                                             Reduction of TNF-α and IL-6.

  Thirunavukkarasu M. 2015^[@R32]^   High                         N:40 (4 groups)\                                          Group1- control\                                                                                                                                                         Western blot analysis and immunohistochemistry, phosphorylated Akt and GSK3-β, nitrotyrosine and caspase-3 expression, echocardiography                             Preservation of myocardium during IRI through upregulation of PI3K/Akt/GSK3β/β-catenin.\
                                                                  rat model of cardiac IRI                                  sham\                                                                                                                                                                                                                                                                                                                                        Increased ejection fraction and fractional shortening and decreased left ventricular internal diameter in\
                                                                                                                            Group 2- aqueous PE extract (100 mg/kg/day PO) for 30 days\                                                                                                                                                                                                                                                                                  electrocardiography of experimental subjects compared to controls.
                                                                                                                            Group 3- control and IRI\                                                                                                                                                                                                                                                                                                                    
                                                                                                                            Group 4- PE and IRI\                                                                                                                                                                                                                                                                                                                         
                                                                                                                            \                                                                                                                                                                                                                                                                                                                                            
  ---------------------------------- ---------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N: sample size, EO: *Emblica officinalis* or Amla or PE: *Phyllanthus emblica*, TC: total cholesterol, TG: triglyceride, LDL: low density lipoprotein, HDL: high density lipoprotein, VLDL: very low density lipoprotein, SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index, hs-CRP: high-sensitivity C reactive protein, EOT: Emblica officinalis tannoids, IRI: Ischemia-reperfusion injury, SOD: superoxide dismutase, TBARS: thiobarbituric acid reactive substances, HUVEC: human umbilical vein endothelial cells, LPS: lipopolysaccharide, HMG-CoA: 3-hydroxy-3-methyl-glutaryl-coenzyme A , PO: orally, DOCA-salt: deoxycorticosterone acetate, LDH: Lactate dehydrogenase

###### Summary of the clinical pharmacological studies regarding the cardiovascular effects of *Emblica officinalis*

  ----------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Author, year**              **JADAD score (out of 5)**   **Level of evidence/study design/**\                                                                                            **Intervention/control group**                                                                                                                           **Outcome measure**                                                                                                                                                                     **Results**
                                                             **participants/inclusion criteria**                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Antony B. 2008^[@R33]^        \<3                          Level II\                                                                                                                       Group1- n:22, aqueous extract of EO 500 mg o.d. PO for 6 months\                                                                                         Serum TC, LDL-C, VLDL-C, TG,\                                                                                                                                                           Reduction of TC, TG, LDL-C, VLDL-C and CRP and increase in\
                                                             quasi-experimental hypercholesterolemic (TC 190 -- 310 mg/dL) patients.                                                         Group 2- n:17, aqueous extract of EO 1000 mg o.d. PO for 6 months                                                                                        HDL-C and CRP                                                                                                                                                                           HDL-C in both groups

  Gopa B., 2012^[@R34]^         \<3                          Level II\                                                                                                                       Group 1- n:40,\                                                                                                                                          Serum TC, TG, LDL-C,VLDL-C, HDL-C                                                                                                                                                       Both treatments reduced TC, LDL-C,VLDL-C and TG and increased HDL-C
                                                             quasi-experimental\                                                                                                             500 mg amla capsule (dried amla fruit juice powder) o.d. PO for 42 days\                                                                                                                                                                                                                                                                         
                                                             N:60, type II hypercholestrolemic patients (TC\>240 mg/dL)                                                                      Group 2- n:20, simvastatin 20 mg o.d. PO for 42 days                                                                                                                                                                                                                                                                                             

  Gopa B, 2012^[@R34]^          \<3                          Level II\                                                                                                                       Group 1- n:28, 500 mg amla capsule o.d. PO for 42 days\                                                                                                  Systolic and diastolic blood pressure                                                                                                                                                   21 patients on amla and 6 on simvastatin therapy showed improvement in blood pressure control
                                                             quasi-experimental\                                                                                                             Group 2- n:10, simvastatin 20 mg o.d. PO for 42 days                                                                                                                                                                                                                                                                                             
                                                             N:38, hypertensive patients (there is not further explanation)                                                                                                                                                                                                                                                                                                                                                                                                                   

  Usharani P 2013^[@R35]^       \>3                          Level I\                                                                                                                        Group1- PE extract 250 mg b.i.d. PO\                                                                                                                     Change in endothelial function identified on salbutamol challenge, changes in serum malondialdehyde, nitric oxide, glutathione, hs-CRP, lipid profile and HbA1c                         Reduction of endothelial reflection index in PE and atorvastatin groups, showing improvement of endothelial function possibly via anti-inflammatory and antioxidant actions.\
                                                             RCT\                                                                                                                            Group 2- PE extract 500 mg b.i.d. PO\                                                                                                                                                                                                                                                                                                            Reduction of serum total cholesterol, LDL-C, VLDL-C, TG, HbA1c, hs-CRP and MDA in PE and atorvastatin groups.\
                                                             N:80\                                                                                                                           Group 3 -atorvastatin 10 mg o.d.PO + placebo\                                                                                                                                                                                                                                                                                                    Increased serum HDL-C, NO and glutathione in PE and atorvastatin groups.
                                                             type 2 diabetic patients\                                                                                                       Group 4 - placebo b.i.d. PO for 12 weeks                                                                                                                                                                                                                                                                                                         
                                                             HbA1c 7%-9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Sinha RR et al 2014^[@R36]^   \<3                          Level I\                                                                                                                        Group1 - n:45, 500 mg amla tablet (dried EO juice) b.i.d. PO for 16 weeks\                                                                               Serum TC, TG, HDL-C, LDL-C and VLDL-C levels, systolic and diastolic blood pressure                                                                                                     Amla was better in decreasing TG and increasing HDL-C,\
                                                             Randomized open label trial,\                                                                                                   Group 2- n:48, atorvastatin 10 mg o.d. PO for 16 weeks                                                                                                                                                                                                                                                                                           atrovastatin was better in decreasing TC, LDL-C and VLDL-C. BP did not significantly change.
                                                             type II hypercholestrolemic (TC\>240 mg/dL and LDL-C\>130 mg/dL) and hypertensive patients (there is not further explanation)                                                                                                                                                                                                                                                                                                                                                    

  Fatima N 2014^[@R37]^         \>3                          Level I\                                                                                                                        Aqueous extract of PE(250 mg) b.i.d. PO for 14 days\                                                                                                     Heart rate, augmentation pressure, augmentation index (AIx), subendocardial viability ratio (SEVR), radial and aortic blood pressure were recorded before and after cold pressor test   PE extract decreased AIx, showing lowered systemic arterial stiffness. The extract reduced radial and aortic BP. It increased SEVR, showing increased myocardial oxygen supply/demand ratio.
                                                             crossover RCT\                                                                                                                  Group 2- placebo capsule contains microcrystalline cellulose (49.7% w/w), lactose (49.5% w/w) and magnesium stearate (0.69% w/w) b.i.d. PO for 14 days                                                                                                                                                                                           
                                                             N: 12 healthy participants                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Fatima N 2014^[@R38]^         \>3                          Level I\                                                                                                                        Group1- 500 mg PE extract\                                                                                                                               Platelet aggregation, bleeding time, clotting time                                                                                                                                      Decrease of platelet aggregation and increase of bleeding and clotting time compared to baseline in all groups\
                                                             Crossover RCT\                                                                                                                  Group 2- 75 mg clopidogrel\                                                                                                                                                                                                                                                                                                                      
                                                             N:10 type 2 diabetic patients                                                                                                   Group 3- 75 mg aspirin\                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                             Group 4-500 mg PE + 75 mg clopidogrel\                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                             Group 5- 500 mg PE + 75 mg aspirin, all as single dose.\                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                             After single dose study and washout period, patients received\                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                             Group 1-500 mg PE extract b.i.d.\                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                             Group 2- 75 mg clopidogrel o.d.\                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                             Group 3- 75 mg aspirin o.d.\                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                             Group 4-combinations for 10 days. All treatments were given PO.                                                                                                                                                                                                                                                                                  

  Khanna S. 2015^[@R39]^        \<3                          Level III\                                                                                                                      Aqueous extract of PE(500 mg) b.i.d. PO for 12 weeks                                                                                                     Serum hs-CRP level and platelet aggregation                                                                                                                                             Decrease in hs-CRP levels and downregulation of ADP- and collagen-induced platelet aggregation
                                                             quasi-experimental\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                             N:15\                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                             overweight/class-1 obese adults ( BMI: 25-35)                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ----------------------------- ---------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

RCT: randomized controlled trial, n: sample size, b.i.d.: two times daily, PO: orally. o.d.: once daily, BMI: body mass index, EO: *Emblica officinalis*, PE: *Phyllanthus emblica*, TC: total cholesterol, TG: triglyceride, LDL: low density lipoprotein, HDL: high density lipoprotein, VLDL: very low density lipoprotein, BP: blood pressure, , hs-CRP: high-sensitivity C reactive protein, BP: blood pressure, MDA: malondialdehyde, Aix: augmentation index, SEVR: subendocardial viability ratio, CPT: cold pressure test, NO: nitric oxide, ADP: Adenosine diphosphate.

The effects given in the results sections of the tables are statistically significant, unless otherwise stated.

Discussion {#s4}
==========

This review collected and presented the evidences concerning the effects of EO on hyperlipidemia, hypertension, myocardial and endothelial function, cardiac specific antioxidants, and coagulation factors.

The results indicate that animal studies constitute the majority of EO-associated cardiovascular research. The plant affects a variety of cardiovascular parameters and has diverse cardiovascular pharmacological activities including antiatherogenic, anticoagulant, antidyslipidemic, antihypertensive, anti-inflammatory, antioxidant, antiplatelet, vasodilatory, and lipid deposition inhibitory effects. Moreover, it improves vascular endothelial function and prevents from both myocardial ischemia/reperfusion injury and doxorubicin and isoproterenol cardiotoxicity.

A few clinical studies have also been performed; nonetheless, the number of high quality clinical studies is not sufficiently large to provide a conclusive proposition on the efficacy of this plant in CVD.

The EO fruit is safe, and no side effects have been reported in clinical studies. In rats, the oral administration of the hydromethanolic (20:80) extract up to 2000 mg/kg over 15 days has not shown any clinical signs of toxicity.^[@R40]^ The animal studies demonstrated that the EO extract has anti-platelet activity and may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants such as warfarin or heparin, anti-platelet drugs such as clopidogrel, and non-steroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen or naproxen. *Phyllanthus emblica* extract interacts pharmacodynamically with clopidogrel and ecosprin in patients with type II diabetes mellitus.^[@R38]^

The EO fruit extract reduces blood sugar levels.^[@R41],[@R42]^ Thus, caution should be taken when using hypoglycemic medications, and patients taking insulin or drugs for diabetes need to be monitored closely. In addition, EO decreases serum lipid levels; hence, cholesterol- or triglyceride-lowering medications should be taken with caution.

EO fruit is also a rich source of tannin and may interfere with intestinal absorption of iron.^[@R43]^

Since EO is a rich source of ascorbic acid, it may trigger gastric hyperacidity and constipation. Alongside this, in the PM literature, it is believed that EO has a cold and dry nature and may have an astringent property. To reduce the astringent effect of EO, it is advised to use as a jam or to consume it together with almond oil and honey.^[@R12]^ These must be considered in patients taking medications for their cardiovascular or other organs' disorders.

Overall, it is concluded that EO affects various cardiovascular disorders and risk factors. However, there is not sufficient clinical evidence to suggest that EO has efficacy in CVD prevention and treatment. Further studies, especially clinical trials, with EO in all fields of cardiovascular pharmacology are needed. Identification of the bioactive compounds and mechanisms mediating the cardiovascular effects of EO is also suggestable.
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